Active 0 6 0 6 O
uncontrolled 7 19 7 19 O
systemic 20 28 20 28 O
bacterial 29 38 29 38 B-chronic_disease
, 38 39 38 39 O
viral 40 45 40 45 B-chronic_disease
, 45 46 45 46 O
or 47 49 47 49 O
fungal 50 56 50 56 B-chronic_disease
infection 57 66 57 66 I-chronic_disease
, 66 67 66 67 O
unstable 68 76 68 76 O
cardiovascular 77 91 77 91 B-chronic_disease
disease 92 99 92 99 I-chronic_disease
, 99 100 99 100 O
or 101 103 101 103 O
other 104 109 104 109 O
systemic 110 118 110 118 B-chronic_disease
disease 119 126 119 126 I-chronic_disease
that 127 131 127 131 O
would 132 137 132 137 O
limit 138 143 138 143 O
compliance 144 154 144 154 O
with 155 159 155 159 O
study 160 165 160 165 O
procedures 166 176 166 176 O

Locally 0 7 177 184 O
- 7 8 184 185 O
advanced 8 16 185 193 O
or 17 19 194 196 O
metastatic 20 30 197 207 O
malignancy 31 41 208 218 B-cancer
with 42 46 219 223 O
an 47 49 224 226 O
NTRK1 50 55 227 232 O
, 55 56 232 233 O
NTRK2 57 62 234 239 O
, 62 63 239 240 O
or 64 66 241 243 O
NTRK3 67 72 244 249 O
gene 73 77 250 254 O
fusion 78 84 255 261 O
identified 85 95 262 272 O
through 96 103 273 280 O
molecular 104 113 281 290 B-treatment
assays 114 120 291 297 I-treatment

Pregnancy 0 9 298 307 B-pregnancy

Prior 0 5 308 313 O
progression 6 17 314 325 O
while 18 23 326 331 O
receiving 24 33 332 341 O
approved 34 42 342 350 O
or 43 45 351 353 O
investigational 46 61 354 369 B-treatment
tyrosine 62 70 370 378 I-treatment
kinase 71 77 379 385 I-treatment
inhibitors 78 88 386 396 I-treatment
targeting 89 98 397 406 O
TRK 99 102 407 410 O

Subjects 0 8 411 419 O
must 9 13 420 424 O
have 14 18 425 429 O
at 19 21 430 432 O
least 22 27 433 438 O
one 28 31 439 442 B-lower_bound
measurable 32 42 443 453 O
lesion 43 49 454 460 O
as 50 52 461 463 O
defined 53 60 464 471 O
by 61 63 472 474 O
RECIST 64 70 475 481 O
v1.1 71 75 482 486 O

Subjects 0 8 487 495 O
must 9 13 496 500 O
have 14 18 501 505 O
received 19 27 506 514 O
prior 28 33 515 520 B-treatment
standard 34 42 521 529 I-treatment
therapy 43 50 530 537 I-treatment
appropriate 51 62 538 549 O
for 63 66 550 553 O
their 67 72 554 559 O
tumor 73 78 560 565 B-cancer
type 79 83 566 570 O
and 84 87 571 574 O
stage 88 93 575 580 O
of 94 96 581 583 O
disease 97 104 584 591 O
, 104 105 591 592 O
or 106 108 593 595 O
in 109 111 596 598 O
the 112 115 599 602 O
opinion 116 123 603 610 O
of 124 126 611 613 O
the 127 130 614 617 O
investigator 131 143 618 630 O
, 143 144 630 631 O
would 145 150 632 637 O
be 151 153 638 640 O
unlikely 154 162 641 649 O
to 163 165 650 652 O
tolerate 166 174 653 661 O
or 175 177 662 664 O
derive 178 184 665 671 O
clinically 185 195 672 682 O
meaningful 196 206 683 693 O
benefit 207 214 694 701 O
from 215 219 702 706 O
appropriate 220 231 707 718 O
standard 232 240 719 727 B-treatment
of 241 243 728 730 I-treatment
care 244 248 731 735 I-treatment
therapy 249 256 736 743 I-treatment

Subjects 0 8 744 752 O
who 9 12 753 756 O
received 13 21 757 765 O
less 22 26 766 770 O
than 27 31 771 775 O
28 32 34 776 778 B-upper_bound
days 35 39 779 783 I-upper_bound
of 40 42 784 786 O
treatment 43 52 787 796 B-treatment
and 53 56 797 800 O
discontinued 57 69 801 813 O
because 70 77 814 821 O
of 78 80 822 824 O
intolerance 81 92 825 836 O
or 93 95 837 839 O
toxicity 96 104 840 848 O
are 105 108 849 852 O
eligible 109 117 853 861 O

Subjects 0 8 862 870 O
with 9 13 871 875 O
asymptomatic 14 26 876 888 O
brain 27 32 889 894 B-cancer
metastases 33 43 895 905 I-cancer
are 44 47 906 909 O
eligible 48 56 910 918 O
to 57 59 919 921 O
participate 60 71 922 933 O
in 72 74 934 936 O
the 75 78 937 940 O
study 79 84 941 946 O

Subjects 0 8 947 955 O
with 9 13 956 960 O
primary 14 21 961 968 O
CNS 22 25 969 972 B-cancer
tumors 26 32 973 979 I-cancer
are 33 36 980 983 O
eligible 37 45 984 992 O

Symptomatic 0 11 993 1004 B-cancer
or 12 14 1005 1007 I-cancer
unstable 15 23 1008 1016 I-cancer
brain 24 29 1017 1022 I-cancer
metastases 30 40 1023 1033 I-cancer

